The Food and Drug Administration on Thursday ordered Juul Labs to stop selling and distributing all of its currently marketed products in the United States, a sweeping regulatory action against the company that became synonymous with the rapid rise of youth vaping. The agency said Juul’s applications did not provide sufficient evidence to demonstrate that its device and pods meet the federal public-health standard required for continued marketing.

The FDA’s June 23 announcement covers the Juul device and four pod products: Virginia tobacco and menthol at nicotine concentrations of 5.0% and 3.0%. The agency said retailers should remove the products from sale and that Juul must stop commercial distribution, although FDA emphasized that it does not enforce tobacco-product requirements against individual consumers for possession or use.

The decision turns on evidence, not an immediate hazard finding

FDA said its scientific review found insufficient and conflicting data in Juul’s premarket tobacco product applications, including questions involving genotoxicity and chemicals that might leach from the company’s proprietary e-liquid pods. The agency said it had not received enough information to complete a full toxicological assessment and therefore could not conclude that marketing the products would be appropriate for the protection of public health.

The distinction is important. FDA did not say it had identified an immediate acute danger from every Juul device already in consumers’ hands. Instead, it said the legal burden belongs to the manufacturer to establish that continued marketing satisfies the Tobacco Control Act’s public-health test. The agency’s marketing-orders database records the June 23 denial orders as part of a broader review of electronic nicotine delivery systems submitted under the premarket tobacco application process.

Michele Mital, acting director of FDA’s Center for Tobacco Products, said manufacturers have the opportunity to provide evidence that their products meet the statutory standard, but Juul left the agency with significant unanswered questions. Without the information needed to determine relevant health risks, FDA said it could not authorize the products.

Juul’s regulatory problem has been building for years

Juul’s position is unusually consequential because the company helped transform the U.S. nicotine market. Its compact device, high-nicotine salt formulation and early popularity among teenagers made it a central target of regulators and public-health officials. In 2019, FDA issued a warning after concluding that Juul had marketed its products as presenting reduced risk without the authorization required for modified-risk tobacco claims.

Youth use has since fallen from its peak, but electronic cigarettes remain a major public-health issue. CDC and FDA’s 2021 National Youth Tobacco Survey report estimated that more than 2 million U.S. middle- and high-school students were current e-cigarette users. Among current users, a large majority reported flavored products, underscoring why federal review focuses on both adult smoking behavior and youth initiation.

The legal standard FDA applies is broader than whether a product is less harmful than combustible cigarettes for an individual adult smoker. The agency must consider population-level effects, including the likelihood that existing smokers will switch completely, the risk that nonsmokers will begin using nicotine, and the consequences for young people.

A high-profile company faces removal from retail shelves

The practical impact of Thursday’s action is immediate if the orders remain in force: Juul’s products may not be sold or distributed in the United States. The Washington Post reported that the action threatens the domestic business of a company that once dominated the vaping market and has spent years trying to recast itself as a tool for adult smokers rather than a product associated with teen use.

Time noted that FDA has authorized some competing electronic-cigarette products while denying marketing applications for many others, illustrating that the agency is not banning the category outright. Instead, manufacturers must submit product-specific evidence and persuade FDA that their products’ likely benefits for adult smokers outweigh broader risks.

Juul has disputed FDA’s conclusions and can pursue administrative or judicial avenues to challenge the orders. But unless the company obtains relief, the decision means its currently marketed U.S. device and pods cannot lawfully remain on store shelves.

The case tests how FDA will regulate a mature vaping market

FDA’s decision comes after years in which the e-cigarette market expanded faster than the regulatory system designed to evaluate it. Congress gave FDA authority over tobacco products in 2009, and the agency later extended that authority to e-cigarettes. Products that were already on the market were allowed to remain temporarily while manufacturers prepared applications, creating a prolonged transition from widespread commercial availability to product-by-product federal review.

That review now has consequences for major brands. CBS News reported that FDA’s denial focuses on whether Juul supplied adequate evidence rather than enforcement against consumers. The agency is effectively saying that market presence and brand recognition do not substitute for the scientific showing required by law.

The decision also highlights a persistent policy tension. Some public-health experts view noncombustible nicotine products as potentially useful for adults who would otherwise smoke cigarettes. Others emphasize that products attractive to young people can create new nicotine dependence and expose users to uncertain long-term risks. FDA’s statutory task requires it to weigh both dimensions at a population level.

For Juul, that balance has now produced the most serious federal action in its history. The company is not merely facing a warning, advertising restriction or youth-marketing investigation. FDA has denied authorization for every Juul product currently marketed in the United States and directed the company to remove them from commerce.

The significance extends beyond one manufacturer. The decision signals that FDA intends to use the premarket review process to determine which vaping products can remain legally available and that unresolved toxicology questions can be enough to deny authorization. For an industry built during years of regulatory transition, the standard is becoming concrete: products must survive a scientific review before they can stay on the U.S. market.